Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

All appraisals

1,189 appraisals, newest first, page 7 of 12
AppraisalMedicine pageNICE recommendationPublishedStatus
Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
NICE TA589
BlinatumomabOptimised24 Jul 2019Current
Nusinersen for treating spinal muscular atrophy
NICE TA588
NusinersenOptimised24 Jul 2019Current
Lenalidomide plus dexamethasone for previously untreated multiple myeloma
NICE TA587
LenalidomideOptimised26 Jun 2019Current
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
NICE TA586
LenalidomideOptimised26 Jun 2019Current
Ocrelizumab for treating primary progressive multiple sclerosis
NICE TA585
OcrelizumabRecommended12 Jun 2019Current
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA584
—Recommended5 Jun 2019Current
Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
NICE TA583
ErtugliflozinOptimised5 Jun 2019Current
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
NICE TA582
CabozantinibTerminated (no company submission)24 May 2019Replaced by TA849
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA581
NivolumabRecommended (Cancer Drugs Fund)15 May 2019Replaced by TA780
Enzalutamide for hormone-relapsed non-metastatic prostate cancer
NICE TA580
EnzalutamideNot recommended15 May 2019Current
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA579
AbemaciclibRecommended (Cancer Drugs Fund)8 May 2019Replaced
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA578
DurvalumabRecommended (Cancer Drugs Fund)1 May 2019Current
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA577
Brentuximab VedotinOptimised24 Apr 2019Current
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal)
NICE TA576
BosutinibTerminated (no company submission)17 Apr 2019Current
Tildrakizumab for treating moderate to severe plaque psoriasis
NICE TA575
—Recommended17 Apr 2019Current
Certolizumab pegol for treating moderate to severe plaque psoriasis
NICE TA574
Certolizumab PegolOptimised17 Apr 2019Current
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA573
DaratumumabRecommended (Cancer Drugs Fund)10 Apr 2019Replaced by TA897
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
NICE TA572
ErtugliflozinRecommended27 Mar 2019Current
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA571
BrigatinibRecommended20 Mar 2019Current
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)
NICE TA570
PembrolizumabTerminated (no company submission)20 Mar 2019Current
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
NICE TA569
PertuzumabOptimised20 Mar 2019Current
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal)
NICE TA568
AbataceptTerminated (no company submission)13 Mar 2019Current
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
NICE TA567
TisagenlecleucelRecommended (Cancer Drugs Fund)13 Mar 2019Replaced by TA933
Cochlear implants for children and adults with severe to profound deafness
NICE TA566
—Recommended Optimised Not recommended7 Mar 2019Current
Benralizumab for treating severe eosinophilic asthma
NICE TA565
BenralizumabOptimised6 Mar 2019
Updated 3 Sep 2019
Current
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)
NICE TA564
DabrafenibTerminated (no company submission)27 Feb 2019Replaced by TA898
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA563
AbemaciclibRecommended27 Feb 2019Current
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE TA562
EncorafenibRecommended27 Feb 2019Current
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
NICE TA561
VenetoclaxRecommended27 Feb 2019Current
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal)
NICE TA560
BevacizumabTerminated (no company submission)20 Feb 2019Current
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
NICE TA559
Axicabtagene CiloleucelRecommended (Cancer Drugs Fund)23 Jan 2019Current
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA558
NivolumabRecommended (Cancer Drugs Fund)23 Jan 2019Replaced by TA684
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA557
PembrolizumabOptimised (Cancer Drugs Fund)10 Jan 2019Replaced by TA683
Darvadstrocel for treating complex perianal fistulas in Crohn’s disease
NICE TA556
—Not recommended9 Jan 2019Current
Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA555
RegorafenibOptimised9 Jan 2019Current
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
NICE TA554
TisagenlecleucelRecommended (Cancer Drugs Fund)21 Dec 2018Replaced by TA975
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA553
PembrolizumabRecommended (Cancer Drugs Fund)19 Dec 2018Current
Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
NICE TA552
DaunorubicinRecommended19 Dec 2018Current
Lenvatinib for untreated advanced hepatocellular carcinoma
NICE TA551
LenvatinibOptimised19 Dec 2018Current
Vandetanib for treating medullary thyroid cancer
NICE TA550
VandetanibNot recommended12 Dec 2018Current
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal)
NICE TA549
DenosumabTerminated (no company submission)5 Dec 2018Current
Decitabine for untreated acute myeloid leukaemia (terminated appraisal)
NICE TA548
DecitabineTerminated (no company submission)5 Dec 2018Current
Tofacitinib for moderately to severely active ulcerative colitis
NICE TA547
TofacitinibRecommended28 Nov 2018Current
Padeliporfin for untreated localised prostate cancer
NICE TA546
—Not recommended21 Nov 2018Current
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
NICE TA545
Gemtuzumab OzogamicinOptimised14 Nov 2018Current
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
NICE TA544
DabrafenibRecommended17 Oct 2018Current
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA543
TofacitinibRecommended3 Oct 2018Current
Cabozantinib for untreated advanced renal cell carcinoma
NICE TA542
CabozantinibRecommended3 Oct 2018Current
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
NICE TA541
—Recommended19 Sep 2018Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA540
PembrolizumabOptimised (Cancer Drugs Fund)3 Sep 2018
Updated 1 May 2024
Current
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
NICE TA539
—Recommended29 Aug 2018Current
Dinutuximab beta for treating neuroblastoma
NICE TA538
DinutuximabRecommended22 Aug 2018Current
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA537
IxekizumabRecommended8 Aug 2018Current
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
NICE TA536
AlectinibRecommended8 Aug 2018Current
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
NICE TA535
Lenvatinib, SorafenibOptimised8 Aug 2018Current
Dupilumab for treating moderate to severe atopic dermatitis
NICE TA534
DupilumabOptimised1 Aug 2018Current
Ocrelizumab for treating relapsing–remitting multiple sclerosis
NICE TA533
OcrelizumabOptimised25 Jul 2018Current
Cenegermin for treating neurotrophic keratitis
NICE TA532
CenegerminNot recommended18 Jul 2018Current
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA531
PembrolizumabOptimised18 Jul 2018Current
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
NICE TA530
NivolumabNot recommended4 Jul 2018Current
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA529
CrizotinibRecommended (Cancer Drugs Fund)4 Jul 2018Current
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
NICE TA528
NiraparibOptimised (Cancer Drugs Fund)4 Jul 2018Replaced by TA784
Beta interferons and glatiramer acetate for treating multiple sclerosis
NICE TA527
—Recommended Not recommended27 Jun 2018Current
Arsenic trioxide for treating acute promyelocytic leukaemia
NICE TA526
Arsenic TrioxideRecommended13 Jun 2018Current
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA525
AtezolizumabRecommended13 Jun 2018Current
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA524
Brentuximab VedotinOptimised13 Jun 2018Current
Midostaurin for untreated acute myeloid leukaemia
NICE TA523
MidostaurinRecommended13 Jun 2018Current
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA522
PembrolizumabRecommended (Cancer Drugs Fund)13 Jun 2018Current
Guselkumab for treating moderate to severe plaque psoriasis
NICE TA521
GuselkumabRecommended13 Jun 2018Current
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
NICE TA520
AtezolizumabOptimised16 May 2018Current
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA519
PembrolizumabRecommended (Cancer Drugs Fund)25 Apr 2018Replaced by TA692
Tocilizumab for treating giant cell arteritis
NICE TA518
—Optimised18 Apr 2018Current
Avelumab for treating metastatic Merkel cell carcinoma
NICE TA517
AvelumabRecommended Recommended (Cancer Drugs Fund)11 Apr 2018
Updated 21 Apr 2021
Current
Cabozantinib for treating medullary thyroid cancer
NICE TA516
CabozantinibRecommended28 Mar 2018Current
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
NICE TA515
EribulinNot recommended28 Mar 2018Current
Regorafenib for previously treated advanced hepatocellular carcinoma
NICE TA514
RegorafenibNot recommended21 Mar 2018Current
Obinutuzumab for untreated advanced follicular lymphoma
NICE TA513
ObinutuzumabRecommended21 Mar 2018Current
Tivozanib for treating advanced renal cell carcinoma
NICE TA512
TivozanibRecommended21 Mar 2018Current
Brodalumab for treating moderate to severe plaque psoriasis
NICE TA511
BrodalumabRecommended21 Mar 2018Current
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA510
DaratumumabOptimised (Cancer Drugs Fund)14 Mar 2018Current
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA509
PertuzumabRecommended7 Mar 2018Current
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
NICE TA508
—Optimised7 Mar 2018Current
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
NICE TA507
—Optimised21 Feb 2018Current
Lesinurad for treating chronic hyperuricaemia in people with gout
NICE TA506
—Not recommended7 Feb 2018Current
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA505
IxazomibOptimised (Cancer Drugs Fund)7 Feb 2018Current
Pirfenidone for treating idiopathic pulmonary fibrosis
NICE TA504
PirfenidoneOptimised6 Feb 2018Current
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
NICE TA503
FulvestrantNot recommended31 Jan 2018Current
Ibrutinib for treating relapsed or refractory mantle cell lymphoma
NICE TA502
IbrutinibOptimised31 Jan 2018Current
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
NICE TA501
—Only in research31 Jan 2018Current
Ceritinib for untreated ALK-positive non-small-cell lung cancer
NICE TA500
CeritinibRecommended24 Jan 2018Current
Glecaprevir–pibrentasvir for treating chronic hepatitis C
NICE TA499
—Recommended24 Jan 2018Current
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
NICE TA498
LenvatinibRecommended24 Jan 2018Current
Golimumab for treating active non-radiographic axial spondyloarthritis
NICE TA497
GolimumabRecommended10 Jan 2018Current
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA496
RibociclibRecommended20 Dec 2017Current
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
NICE TA495
PalbociclibRecommended20 Dec 2017Current
Naltrexone–bupropion for managing overweight and obesity
NICE TA494
Naltrexone, BupropionNot recommended12 Dec 2017Current
Cladribine tablets for treating relapsing–remitting multiple sclerosis
NICE TA493
CladribineOptimised6 Dec 2017Replaced by TA616
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA492
AtezolizumabRecommended (Cancer Drugs Fund)6 Dec 2017Replaced by TA739
Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA491
IbrutinibRecommended (Cancer Drugs Fund)22 Nov 2017Replaced by TA795
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA490
NivolumabRecommended (Cancer Drugs Fund)22 Nov 2017Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.